Role of miR‑34 in gastric cancer: From bench to bedside (Review)
- Authors:
- Shengwei Xiong
- Mingli Hu
- Chenyu Li
- Xiaodong Zhou
- Hongxia Chen
-
Affiliations: Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Obstetrics and Gynecology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China - Published online on: August 16, 2019 https://doi.org/10.3892/or.2019.7280
- Pages: 1635-1646
This article is mentioned in:
Abstract
 |
 |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Plummer M, Franceschi S, Vignat J, Forman D and Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136:487–490. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tsugane S and Sasazuki S: Diet and the risk of gastric cancer: Review of epidemiological evidence. Gastric Cancer. 10:75–83. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pasquinelli AE: MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dingli D and Michor F: Successful therapy must eradicate cancer stem cells. Stem Cells. 24:2603–2610. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dontu G, Al-Hajj M, Abdallah WM, Clarke MF and Wicha MS: Stem cells in normal breast development and breast cancer. Cell Prolif. 36 (Suppl 1):S59–S72. 2003. View Article : Google Scholar | |
|
Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D and Xu L: Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 8:2662008. View Article : Google Scholar : PubMed/NCBI | |
|
Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voûte PA, Delattre O, Laureys G, Van Roy N, et al: 1p36: every subband a suppressor? Eur J Cancer 31A. 538–541. 1995. View Article : Google Scholar | |
|
Rodriguez A, Griffiths-Jones S, Ashurst JL and Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res. 14:1902–1910. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumour suppressor network. Nature. 447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Krawetz SA, Kruger A, Lalancette C, Tagett R, Anton E, Draghici S and Diamond MP: A survey of small RNAs in human sperm. Hum Reprod. 26:3401–3412. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jafari N and Abediankenari S: MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell. Tumour Biol. 39:10104283177016522017. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G and Hermeking H: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yamakuchi M, Ferlito M and Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, Larsson LG and Hermeking H: The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA. 109:E187–E196. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mandke P, Wyatt N, Fraser J, Bates B, Berberich SJ and Markey MP: MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One. 7:e420342012. View Article : Google Scholar : PubMed/NCBI | |
|
Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M and Lund AH: p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 17:236–245. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Welch C, Chen Y and Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 26:731–743. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rokavec M, Li H, Jiang L and Hermeking H: The p53/miR-34 axis in development and disease. J Mol Cell Biol. 6:214–230. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z and Zheng X: Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 582:1564–1568. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M and Allgayer H: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 30:2888–2899. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Li D, Kovalchuk I, Apel IJ, Chinnaiyan AM, Wóycicki RK, Cantor CR and Kovalchuk O: miR-34a directly targets tRNAiMet precursors and affects cellular proliferation, cell cycle, and apoptosis. Proc Natl Acad Sci USA. 115:7392–7397. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grammatikakis I, Gorospe M and Abdelmohsen K: Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci. 14:1822–1842. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Huang T, Siu HL, Wong CC, Dong Y, Wu F, Zhang B, Wu WK, Cheng AS, Yu J, et al: IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol Cancer. 16:772017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang AM, Huang TT, Hsu KW, Huang KH, Fang WL, Yang MH, Lo SS, Chi CW, Lin JJ and Yeh TS: Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget. 5:5002–5016. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mert U, Ozgür E, Tiryakioglu D, Dalay N and Gezer U: Induction of p53-inducible microRNA miR-34 by gamma radiation and bleomycin are different. Front Genet. 3:2202012. View Article : Google Scholar : PubMed/NCBI | |
|
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B: A model for p53-induced apoptosis. Nature. 389:300–305. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Shen Z, Zhan G, Ye D, Ren Y, Cheng L, Wu Z and Guo J: MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol. 29:2473–2480. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Deng X, Zheng H, Li D, Xue Y, Wang Q, Yan S, Zhu Y and Deng M: MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1. Exp Ther Med. 15:3705–3714. 2018.PubMed/NCBI | |
|
Lin L, Jiang H, Huang M, Hou X, Sun X, Jiang X, Dong X, Sun X, Zhou B and Qiao H: Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway. Oncol Rep. 34:663–672. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS, Bae JM, et al: MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 26:1632–1641. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pu Y, Zhao F, Wang H and Cai S: miR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci Rep. 7:442182017. View Article : Google Scholar : PubMed/NCBI | |
|
Krause CJ, Popp O, Thirunarayanan N, Dittmar G, Lipp M and Müller G: MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR. Oncotarget. 7:10414–10432. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T, et al: Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci. 98:1845–1852. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hao Q, Lu X, Liu N, Xue X, Li M, Zhang C, Qin X, Li W, Shu Z, Song B, et al: Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development. BMB Rep. 46:316–321. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G, Jiang C, Li D, Wang R and Wang W: miRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 35:9801–9806. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Fan R, Wang L, Cheng S, Li H, Jiang J, Geng M, Jin Y and Wu Y: Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumor Biol. 34:963–971. 2013. View Article : Google Scholar | |
|
Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y and Wu Y: miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 35:1287–1295. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Y, Guo JJ, Liu YM and Wu XL: MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep. 34(pii): e001122014.PubMed/NCBI | |
|
He M, Gao L, Zhang S, Tao L, Wang J, Yang J and Zhu M: Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer. 17:431–441. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wei B, Huang QY, Huang SR, Mai W and Zhong XG: MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep. 12:5255–5261. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Kong Y, Yang W, Ma F, Zhang Y, Ji S, Ma EM, Liu H, Chen Y and Hua Y: Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep. 36:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu YW, Sun M, Xia R, Zhang EB, Liu XH, Zhang ZH, Xu TP, De W, Liu BR and Wang ZX: LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death. 6:e18022015. View Article : Google Scholar | |
|
Hu Y, Pu Q, Cui B and Lin J: MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting Tgif2. Int J Clin Exp Pathol. 8:8921–8928. 2015.PubMed/NCBI | |
|
Jang E, Kim E, Son HY, Lim EK, Lee H, Choi Y, Park K, Han S, Suh JS, Huh YM and Haam S: Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Biomaterials. 105:12–24. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim S-M, Hur DY, Hong SW and Kim JH: EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells. Biochem Biophys Res Commun. 494:550–555. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bader AG: miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 3:1202012. View Article : Google Scholar : PubMed/NCBI | |
|
Hui WT, Ma XB, Zan Y, Wang XJ and Dong L: Prognostic significance of miR-34a expression in patients with gastric cancer after radical gastrectomy. Chin Med J (Engl). 128:2632–2637. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ and Green JE: miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics. 4:792011. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, et al: Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 31:2066–2073. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stánitz E, Juhász K, Tóth C, Gombos K, Natali PG and Ember I: Evaluation of MicroRNA expression pattern of gastric adenocarcinoma associated with socioeconomic, environmental and lifestyle factors in northwestern Hungary. Anticancer Res. 33:3195–3200. 2013.PubMed/NCBI | |
|
Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 34:537–542. 2009.PubMed/NCBI | |
|
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI | |
|
Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J and Tsukada K: MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett. 2:613–619. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J, Yang Q, Xu Y and Li F: Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 13:468–475. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M and Moriyama M: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, Kao HW, Fang WL, Huang KH, Chan WC and Lin WC: Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 129:2600–2610. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Hu X, Zhou H, Shi G and Wu J: Identification of aberrantly expressed miRNAs in gastric cancer. Gastroenterol Res Pract. 2014:4738172014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Li S, Yang J, Liu S, Gong X and Yu X: The prognostic value of miR-34a expression in completely resected gastric cancer: Tumor recurrence and overall survival. Int J Clin Exp Med. 8:2635–2641. 2015.PubMed/NCBI | |
|
Yang B, Huang J, Liu H, Guo W and Li G: miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells. Tumour Biol. 37:1771–1779. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Yu J, Xu J, Zheng C, Li X and Du J: The analysis of microRNA-34 family expression in human cancer studies comparing cancer tissues with corresponding pericarcinous tissues. Gene. 554:1–8. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hanazono K, Natsugoe S, Stein HJ, Aikou T, Hoefler H and Siewert JR: Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression. Oncol Rep. 15:821–824. 2006.PubMed/NCBI | |
|
Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH and Hermeking H: Nikitin AYFrequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 16:1119–1128. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking H: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 7:2591–2600. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gal-Yam EN, Saito Y, Egger G and Jones PA: Cancer epigenetics: Modifications, screening, and therapy. Annu Rev Med. 59:267–280. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu S, Hu Y and Cai T: Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep. 5:97872015. View Article : Google Scholar : PubMed/NCBI | |
|
Noto JM and Peek RM: The role of microRNAs in Helicobacter pylori pathogenesis and gastric carcinogenesis. Front Cell Infect Microbiol. 1:212012. View Article : Google Scholar : PubMed/NCBI | |
|
Chang H, Kim N, Park JH, Nam RH, Choi YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JM and Lee DH: Different microRNA expression levels in gastric cancer depending on Helicobacter pylori infection. Gut Liver. 9:188–196. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Liu G, Ye Y, Fu Y and Zhang X: Upregulation of miR-34a by diallyl disulfide suppresses invasion and induces apoptosis in SGC-7901 cells through inhibition of the PI3K/Akt signaling pathway. Oncol Lett. 11:2661–2667. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, et al: Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. FEBS J. 281:115–128. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tang T, Su R, Wang B and Zhang Y: An integrated approach of predicted miR-34a targets identifies a signature for gastric cancer. Oncol Lett. 10:653–660. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, Kimura T, Harada T, Ashida M, Niinuma T, et al: Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol. 49:1135–1144. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Saunders MA, Liang H and Li WH: Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA. 104:3300–3305. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cai M, Zhang Y, Ma Y, Li W, Min P, Qiu J, Xu W, Zhang M, Li M, Li L, et al: Association between microRNA-499 polymorphism and gastric cancer risk in Chinese population. Bull Cancer. 102:973–978. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang J, Jia ZF, Cao DH, Wu YH, Sun ZW and Cao XY: Association of the miR-146a rs2910164 polymorphism with gastric cancer susceptibility and prognosis. Future Oncol. 12:2215–2226. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H and Hu Z: A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 128:412–417. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C, Ma X, Liu D, Wang Y, Tang R, Zhu Y, Xu Z and Yang L: Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population. Tumour Biol. 35:12545–12554. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pan XM, Sun RF, Li ZH, Guo XM, Qin HJ and Gao LB: Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomarkers. 19:198–202. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Diao S, Li J, Ma B and Yuan S: An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk. Oncotarget. 8:28888–28896. 2017.PubMed/NCBI | |
|
Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, Wei J, Chen X, Weng Y, He T and Zhang H: Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 27:443–452. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al: PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 108(pii): djv3032015.PubMed/NCBI | |
|
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res. 18:6260–6270. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, et al: In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 9:e900052014. View Article : Google Scholar : PubMed/NCBI | |
|
Daige CL, Wiggins JF, Priddy L, Nelligan-Davis T, Zhao J and Brown D: Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther. 13:2352–2360. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S and Hong DS: Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 35:180–188. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X and Chang C: Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Lett. 373:45–56. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yan LH, Chen ZN, Li L, Chen J, Mo XW, Qin YZ, Wei WE, Qin HQ, Lin Y and Chen JS: E2F-1 promotes DAPK2-induced anti-tumor immunity of gastric cancer cells by targeting miR-34a. Tumor Biol. Oct 4–2016.(Epub ahead of print). View Article : Google Scholar |
